New Drug Trial Aims to Stop Ebola Before Symptoms

In eastern Congo, a significant trial is testing an experimental antiviral pill, obeldesivir, with the goal of preventing Ebola infection after exposure. Over 250 individuals have enrolled in this crucial study, which is designed to administer the drug soon after suspected contact to halt the disease before symptoms manifest. This strategy is termed post-exposure prophylaxis (PEP).

The trial is a pivotal effort to combat the ongoing Ebola outbreak, described as the deadliest in the Central African country's history. The World Health Organization notes that the outbreak continues to outpace containment efforts. Participants in the trial include those exposed to the virus, such as health workers and relatives of patients.

Coordinated by the medical nonprofit ALIMA, the trial aims to recruit nearly 1,000 participants. If obeldesivir proves effective, it could significantly break the chain of infection, differing from vaccines which require time to provide protection and curative treatments used after symptom onset.

The outbreak, declared in mid-May, has resulted in at least 8,300 confirmed cases and 4,000 deaths, spreading across seven provinces. Efforts to track and slow the virus continue, with the hope that this trial will provide a vital new tool against the deadly disease.